- Home
- MNOV vs ATYR Comparison
MNOV vs ATYR Comparison
Compare MNOV & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | ATYR |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.5M | 79.2M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MNOV | ATYR |
|---|---|---|
| Price | $1.50 | $0.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.00 | ★ $8.75 |
| AVG Volume (30 Days) | 101.9K | ★ 2.8M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $257,917.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.13 | $0.64 |
| 52 Week High | $2.24 | $7.29 |
Technical Indicators
Market Signals| Indicator | MNOV | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 44.28 |
| Support Level | $1.50 | $0.70 |
| Resistance Level | $1.60 | $0.83 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 68.42 | 62.02 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.